Abstract:Abstract Medulloblastoma (MB) is the most common type of childhood brain cancer worldwide. Although current treatment with surgery and extensive chemoradiation has led to increased survival rates, many MB patients still die from the disease. Moreover, surviving patients suffer severe long-term side effects as a consequence of treatment. It is therefore crucial to develop more effective and less toxic therapies. The most aggressive subtype of MB tumors often exhibits amplification or overexpression of the MYC oncogene. Patients with MYC-amplified MB exhibit a high frequency of cerebrospinal tumor dissemination, often experience treatment resistance and have extremely poor prognoses. While the MYC oncogene is established as the oncogenic driver in Group 3 MB, it has remained undruggable. Thus, targeting regulatory components of MYC and the signaling pathways regulated by it is of great potential therapeutic value. Studies have revealed that MB has very few germline mutations in cancer predisposition genes, suggesting that dysregulated epigenetic pathways might be critical in MB pathogenesis. Particularly, dysregulation of epigenetic modifiers, including histone methyltransferases and histone demethylases, is very common in Group 3 MB, compared to other MB subgroups. Therefore, it is important to identify such epigenetic modifiers that may have controls on MYC and its tumorigenic activities and explore these as the epigenetic drug-candidate targets in Group 3 (MYC-driven) MB. In this regard, we found that protein arginine demethylase Jumonji C domain-containing protein 6 (JMJD6), an emerging key epigenetic enzyme in cancers, is a novel regulator of MYC expression in MYC-driven MB. We observed high levels of JMJD6 that not only mirror MYC expression in the most aggressive MB but also correlate with poor outcomes in these patients. Knockdown of JMJD6 decreased MYC expression, cellular proliferation/survival and stemness in MYC-amplified MB cells. Mechanistically, our results revealed that JMJD6 forms complexes with proteins involved in maintaining and regulating the promoter-pause at super-enhancers, suggesting that JMJD6 can regulate MYC at the transcription level. Moreover, our in vivo analyses of JMJD6 inhibition, either with inducible gene knockdown or a pharmacologic small molecule inhibitor, demonstrated anti-MB potential with suppressed MYC expression. Based on this background and preliminary observations, we hypothesize that JMJD6 plays crucial roles in the most aggressive MB by regulating MYC expression and hence MYC-driven tumorigenesis. Accordingly, we hypothesize that targeting the JMJD6-MYC axis by JMJD6 inhibition can serve as a powerful therapeutic strategy for MYC-driven MB. Citation Format: Matthew Kling, Devendra Kumar, Sutapa Ray, Shantaram Joshi, Don Coulter, Nagendra K. Chaturvedi. JMJD6 as a novel tumorigenic factor and therapeutic target in group 3 (MYC-driven) medulloblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3346.

JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

High Expression of JMJD6 Predicts Unfavorable Survival in Lung Adenocarcinoma

JMJD5 Interacts with P53 and Negatively Regulates P53 Function in Control of Cell Cycle and Proliferation.

JMJD6 Promotes Melanoma Carcinogenesis Through Regulation of the Alternative Splicing of PAK1, a Key MAPK Signaling Component

632PPatient-derived xenografts (PDX) identify JMJD6 inhibitor as an effective therapeutic medicine in colorectal cancer

Jumonji Domain-Containing Protein 6 Functions As a Marker of Head and Neck Squamous Cell Carcinoma at Advanced Stage with No Effect on Prognosis

JMJD5 Inhibits Lung Cancer Progression by Facilitating EGFR Proteasomal Degradation

Jumonji Domain-Containing 6 (JMJD6) Identified As a Potential Therapeutic Target in Ovarian Cancer

Expression and Prognosis Analysis of JMJD5 in Human Cancers

JMJD8 Is an M2 Macrophage Biomarker, and It Associates With DNA Damage Repair to Facilitate Stemness Maintenance, Chemoresistance, and Immunosuppression in Pan-Cancer

JMJD6 is a Tumorigenic Factor and Therapeutic Target in Neuroblastoma

Expression and Prognosis Analysis of JMJD5 in Human Cancers.

JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity

Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response

MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer

The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients

Abstract 3346: JMJD6 as a novel tumorigenic factor and therapeutic target in group 3 (MYC-driven) medulloblastoma

JMJD3 Enhances Invasiveness and Migratory Capacity of Non-Small Cell Lung Cancer Cell Via Activating EMT Signaling Pathway.

Elevated JMJD1A is a Novel Predictor for Prognosis and a Potential Therapeutic Target for Gastric Cancer.

JMJD2A Contributes to Breast Cancer Progression Through Transcriptional Repression of the Tumor Suppressor ARHI

A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo.